NEW YORK (GenomeWeb News) – Genomic Health said today that it has accelerated development of its prostate cancer test with the goal of launching it in 2013, a year earlier than it had previously estimated.
The firm also said that Israeli insurance firm Clalit has agreed to provide reimbursement for its Oncotype Dx colon cancer test and that it expects to report results from a second recurrence study in stage II colon cancer in 2011.
Genomic Health said that it decided to speed up development of the prostate cancer test based on positive top-line results of a large gene identification study that it presented in December at the Society for Urologic Oncology annual meeting.
The study, which analyzed expression signatures for 431 prostate cancers among patients previously treated with radical prostatectomy, identified 295 genes that were "strongly associated" with clinical recurrence in that population, Genomic Health said.
The company and research partners from the Cleveland Clinic plan to present complete data from the study at the American Society of Clinical Oncology Genitourinary Cancer Symposium in February.